Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net income | $89 | $47 |
| Adjustments to reconcile net income to net cash from operating activities: | ||
| Depreciation and amortization | 2 | 3 |
| Amortization of right-of-use assets | 2 | 2 |
| Stock-based compensation expense | 9 | 6 |
| Impairment of tangible and intangible assets | 6 | — |
| Loss on debt extinguishment | 18 | — |
Item 1. Unaudited Condensed Financial Statements.
FAQ
- What is Indivior Pharmaceuticals, Inc.'s D&A?
- Indivior Pharmaceuticals, Inc. (INDV) reported D&A of $2M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc.'s D&A changed year-over-year?
- Indivior Pharmaceuticals, Inc.'s D&A decreased by 33.3% year-over-year, from $3M to $2M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc.'s D&A?
- Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc.'s D&A has grown at a -14.5% compound annual growth rate (CAGR), from $16M to $10M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Indivior Pharmaceuticals, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude